Holen Sie sich die Stockscreener-App
23.40
3.51%
-0.85
Handel nachbörslich:
23.40
Schlusskurs vom Vortag:
$24.25
Offen:
$24.15
24-Stunden-Volumen:
754.77K
Relative Volume:
0.64
Marktkapitalisierung:
$2.86B
Einnahmen:
$588.99M
Nettoeinkommen (Verlust:
$214.33M
KGV:
13.89
EPS:
1.6844
Netto-Cashflow:
$208.61M
1W Leistung:
+2.68%
1M Leistung:
+1.39%
6M Leistung:
+19.88%
1J Leistung:
-5.80%
1-Tages-Spanne:
$23.39
$24.29
1-Wochen-Bereich:
$22.92
$24.58
52-Wochen-Spanne:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
23.40 | 2.86B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - MSN
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes - TradingView
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Australia
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Strong Buy" by Brokerages - MarketBeat
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard realigns reporting; Catalyst Pharmaceuticals (CPRX) shows 0% ownership - Stock Titan
Truist Financial Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to "Strong-Buy" - MarketBeat
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView
Aug Technicals: Can Catalyst Pharmaceuticals Inc stock outperform in a bear market2026 Price Targets & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Retail Trends: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Market WrapUp & Low Drawdown Momentum Ideas - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer - TradingView
Will Catalyst Pharmaceuticals Inc benefit from government policyWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Is Catalyst Pharmaceuticals Inc a momentum stock2026 Growth vs Value & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum Cooldown - Sahm
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
CPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance Australia
Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Market Wrap: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Weekly Recap & Weekly Watchlist of Top Performers - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan
Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ - Minichart
Catalyst Pharma Patent Trial Against Hetero USA Delayed - TipRanks
Catalyst Pharmaceuticals IncDistrict court delays bench trial to May 18, 2026SEC filing - marketscreener.com
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026 - Stock Titan
Catalyst Pharmaceuticals (CPRX) reports record Q4 and full year 2025 results - MSN
Catalyst Pharmaceuticals, Inc. (CPRX): A bull case theory - MSN
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Analyst Upgrade: Is Catalyst Pharmaceuticals Inc a defensive stock2026 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
(CPRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Aug Rallies: Should I trade or invest in Catalyst Pharmaceuticals IncOptions Play & Community Verified Trade Signals - baoquankhu1.vn
Merger Talk: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Macro Moves & Weekly Setup with High ROI Potential - baoquankhu1.vn
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? - Yahoo Finance
Here's why Catalyst Pharmaceutical (CPRX) is a strong value stock - MSN
Is Catalyst Pharmaceuticals (CPRX) Offering Value After Strong Multi‑Year Share Price Gains - simplywall.st
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Weakness - Sahm
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics - MarketBeat
Fundsmith LLP Acquires 654,721 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - TradingView
Kennedy Capital Management LLC Grows Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
EPS Watch: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
2025 results exceed expectations as 2026 outlook set, Catalyst Pharmaceuticals projects - Traders Union
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Fieldview Capital Management LLC - MarketBeat
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.03%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):